Health Care & Life Sciences » Biotechnology | RedHill Biopharma Ltd.

RedHill Biopharma Ltd. ADR | Balance Sheet

Fiscal year is January-December. All values ILS Thousands.
2013
2014
2015
2016
2017
2018
Cash & Short Term Investments
42,044.20
89,289.30
226,217.90
254,603.60
160,407.60
198,739
Total Accounts Receivable
1,482.10
4,140.50
856.00
1,893.50
7,852.90
5,212.80
Inventories
-
-
-
-
10,689.20
7,802.30
Other Current Assets
211.70
7,821.80
8,373.50
4,499.10
451.30
448.40
Total Current Assets
43,738.10
101,251.60
235,447.40
260,996.20
179,401.00
212,202.60
Net Property, Plant & Equipment
357.50
568.20
482.50
635.00
798.50
609.10
Total Investments and Advances
281.20
295.80
521.40
527.30
527.70
523.10
Intangible Assets
5,397.40
10,176.10
23,579.80
23,457.50
18,347.70
19,879.50
Total Assets
49,774.10
112,291.70
260,031.10
285,616.00
199,074.80
233,214.30
Accounts Payable
3,061.40
256.80
463.00
230.90
16,681.30
Other Current Liabilities
5,321.00
6,436.50
20,992.20
20,382.50
24,388.30
Total Current Liabilities
8,382.50
6,693.30
21,455.30
20,613.40
41,069.60
Other Liabilities
-
8,269.30
4,813.20
23,688.40
1,555.30
Total Liabilities
8,382.50
14,962.60
26,268.50
44,301.80
42,624.90
Common Equity (Total)
41,391.70
97,329.10
233,762.60
241,314.20
156,449.90
Total Shareholders' Equity
41,391.70
97,329.10
233,762.60
241,314.20
156,449.90
Total Equity
41,391.70
97,329.10
233,762.60
241,314.20
156,449.90
Liabilities & Shareholders' Equity
49,774.10
112,291.70
260,031.10
285,616.00
199,074.80

About RedHill Biopharma

View Profile
Address
21 Ha'arba'a Street
Tel Aviv TA 64739
Israel
Employees -
Website http://www.redhillbio.com
Updated 07/08/2019
RedHill Biopharma Ltd. is a specialty biopharmaceutical company primarily focused on the development and commercialization of late clinical-stage, proprietary drugs for the treatment of gastrointestinal diseases. RedHill's pipeline includes several drug candidates in advanced clinical development stages, including three Phase III-stage programs. Its late clinical-stage pipeline includes TALICIA® (RHB-105) for Helicobacter pylori infection; RHB-104 for Crohn's disease; RHB-204 for nontuberculous mycobacteria (NTM) infections; BEKINDA® (RHB-102) for acute gastroenteritis and gastritis and IBS-D; YELIVA® (ABC294640) for cholangiocarcinoma and targeting multiple other oncology, inflammatory and gastrointestinal indications; RHB-106, an encapsulated bowel preparation licensed to Salix Pharmaceuticals, Ltd. and RHB-107, targeting cancer and inflammatory gastrointestinal diseases.